BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 32250220)

  • 21. Chemokine and cytokine levels in inflammatory bowel disease patients.
    Singh UP; Singh NP; Murphy EA; Price RL; Fayad R; Nagarkatti M; Nagarkatti PS
    Cytokine; 2016 Jan; 77():44-9. PubMed ID: 26520877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging immunological targets in inflammatory bowel disease.
    Monteleone G; Pallone F; MacDonald TT
    Curr Opin Pharmacol; 2011 Dec; 11(6):640-5. PubMed ID: 22000933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease.
    Furfaro F; Alfarone L; Gilardi D; Correale C; Allocca M; Fiorino G; Argollo M; Zilli A; Zacharopoulou E; Loy L; Roda G; Danese S
    Curr Drug Targets; 2021; 22(7):760-769. PubMed ID: 33475057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current scenario in inflammatory bowel disease: drug development prospects.
    Chandel S; Prakash A; Medhi B
    Pharmacol Rep; 2015 Apr; 67(2):224-9. PubMed ID: 25712643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More.
    Misselwitz B; Juillerat P; Sulz MC; Siegmund B; Brand S;
    Digestion; 2020; 101 Suppl 1():69-82. PubMed ID: 32570252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allergic and Immunologic Perspectives of Inflammatory Bowel Disease.
    Clarke K; Chintanaboina J
    Clin Rev Allergy Immunol; 2019 Oct; 57(2):179-193. PubMed ID: 29754190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biologic targeting in the treatment of inflammatory bowel diseases.
    Bosani M; Ardizzone S; Porro GB
    Biologics; 2009; 3():77-97. PubMed ID: 19707398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modeling Inflammatory Bowel Disease by Intestinal Organoids.
    Di Giorgio C; Roselli R; Biagioli M; Bordoni M; Ricci P; Zampella A; Distrutti E; Donini A; Fiorucci S
    Recent Adv Inflamm Allergy Drug Discov; 2023; 17(1):39-53. PubMed ID: 36411558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral locally active steroids in inflammatory bowel disease.
    Nunes T; Barreiro-de Acosta M; Marin-Jiménez I; Nos P; Sans M
    J Crohns Colitis; 2013 Apr; 7(3):183-91. PubMed ID: 22784947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent advances in the treatment of IBD: Targets, mechanisms and related therapies.
    Liu J; Di B; Xu LL
    Cytokine Growth Factor Rev; 2023; 71-72():1-12. PubMed ID: 37455149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biologic therapy for inflammatory bowel disease.
    Ardizzone S; Bianchi Porro G
    Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Roles of Gut Bacteriophages in the Pathogenesis and Treatment of Inflammatory Bowel Disease.
    Qv L; Mao S; Li Y; Zhang J; Li L
    Front Cell Infect Microbiol; 2021; 11():755650. PubMed ID: 34900751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Deep View of the Biological Property of Interleukin-33 and Its Dysfunction in the Gut.
    Wang Y; He C; Xin S; Liu X; Zhang S; Qiao B; Shang H; Gao L; Xu J
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease.
    Laverny G; Penna G; Vetrano S; Correale C; Nebuloni M; Danese S; Adorini L
    Immunol Lett; 2010 Jun; 131(1):49-58. PubMed ID: 20350569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Roles of Inflammation, Nutrient Availability and the Commensal Microbiota in Enteric Pathogen Infection.
    Stecher B
    Microbiol Spectr; 2015 Jun; 3(3):. PubMed ID: 26185088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inflammatory Bowel Disease Drugs: A Focus on Autophagy.
    Hooper KM; Barlow PG; Stevens C; Henderson P
    J Crohns Colitis; 2017 Jan; 11(1):118-127. PubMed ID: 27381462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Inflammatory bowel diseases (IBD) -- critical discussion of etiology, pathogenesis, diagnostics, and therapy].
    Ochsenkühn T; Sackmann M; Göke B
    Radiologe; 2003 Jan; 43(1):1-8. PubMed ID: 12552369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Introduction and overview: recent advances in the immunotherapy of inflammatory bowel disease.
    Hibi T; Inoue N; Ogata H; Naganuma M
    J Gastroenterol; 2003 Mar; 38 Suppl 15():36-42. PubMed ID: 12698869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.